SFA Stock Overview
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв5.78 |
| 52 Week High | лв6.68 |
| 52 Week Low | лв5.56 |
| Beta | -0.026 |
| 1 Month Change | 1.40% |
| 3 Month Change | -2.69% |
| 1 Year Change | 1.05% |
| 3 Year Change | 29.60% |
| 5 Year Change | 70.00% |
| Change since IPO | -6.58% |
Recent News & Updates
Recent updates
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit
Sep 07
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly
Jun 02Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet
Apr 09Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching
Feb 20How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?
Feb 05Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?
Jan 22Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet
Jan 06
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years
Dec 22Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Dec 07Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?
Nov 19Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Jul 07Shareholder Returns
| SFA | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -0.02% |
| 1Y | 1.0% | -1.0% | 12.6% |
Return vs Industry: SFA exceeded the BG Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: SFA underperformed the BG Market which returned 12.3% over the past year.
Price Volatility
| SFA volatility | |
|---|---|
| SFA Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in BG Market | 8.2% |
| 10% least volatile stocks in BG Market | 2.5% |
Stable Share Price: SFA has not had significant price volatility in the past 3 months compared to the BG market.
Volatility Over Time: SFA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 5,379 | Ognian Donev | www.sopharmagroup.com |
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing.
Sopharma AD Fundamentals Summary
| SFA fundamental statistics | |
|---|---|
| Market cap | лв957.99m |
| Earnings (TTM) | лв81.91m |
| Revenue (TTM) | лв2.05b |
11.7x
P/E Ratio0.5x
P/S RatioIs SFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFA income statement (TTM) | |
|---|---|
| Revenue | лв2.05b |
| Cost of Revenue | лв1.60b |
| Gross Profit | лв451.40m |
| Other Expenses | лв369.49m |
| Earnings | лв81.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 21.97% |
| Net Profit Margin | 3.99% |
| Debt/Equity Ratio | 36.3% |
How did SFA perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield33%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:17 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sopharma AD is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mihail Dimitrov | First Financial Brokerage House |
| Bram Buring | Wood & Company |